What is Collegium Pharmaceutical, Inc.'s SG&A?

Collegium Pharmaceutical, Inc. (COLL) reported SG&A of $106.59M in Q2 2026.

How has Collegium Pharmaceutical, Inc.'s SG&A changed year-over-year?

Collegium Pharmaceutical, Inc.'s SG&A increased by 44.8% year-over-year, from $73.64M to $106.59M.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s SG&A?

Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s SG&A has grown at a 24.4% compound annual growth rate (CAGR), from $118.96M to $284.8M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Collegium Pharmaceutical, Inc. (COLL) SG&A

Screener

SG&A at other companies

Indivior Pharmaceuticals, Inc.INDV

$124M-6.8%

Scilex Holding CompanySCLX

$31.03M+10.6%

AVN

AVNSAVNS

$77.7M+2.6%

Pacira BioSciences, Inc.PCRX

$93.94M+8.3%

BioventusBVS

$82.74M+4.6%

OrganonOGN

$424M+1.0%

Other financials

Income statement

See full

Revenue$199.9M+6.3%

Gross profit$110.3M+1.8%

Operating income$3.7M-89.5%

Net income-$15.1M-226%

EPS (diluted)-$0.46-235%

Balance sheet

See full

Cash & equivalents$150.4M+8.8%

Total debt$5.0M-19.8%

Total equity$311.9M+34.3%

Total assets$2.1B+34.1%

Cash flow

See full

Operating cash flow$71.3M-1.5%

CapEx$496.0K+663%

Free cash flow$70.8M-2.1%

Valuation

See full

Market cap$944.15M-1.3%

Enterprise value$798.74M-3.1%

P/E19.7×-6.7×

P/S1.2×-0.2×

Profitability

See full

Gross margin60%+3.3pp

Operating margin19.5%+1.1pp

Net margin5.9%+0.8pp

FCF margin40.6%+10.8pp

Returns & leverage

See full

Return on equity17.6%+1.4pp

Debt / equity0×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:34 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053851

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Total cost of product revenues	89,586	79,616	165,860	160,049
Gross profit	110,292	108,384	227,538	205,708
Operating expenses
Selling, general and administrative	106,594	73,637	192,944	150,060
Gain on fair value remeasurement of contingent consideration	—	(358)	—	(1,144)
Total operating expenses	106,594	73,279	192,944	148,916
Income from operations	3,698	35,105	34,594	56,792
Interest expense	(19,519)	(20,463)	(35,381)	(41,253)

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s SG&A?: Collegium Pharmaceutical, Inc. (COLL) reported SG&A of $106.59M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s SG&A changed year-over-year?: Collegium Pharmaceutical, Inc.'s SG&A increased by 44.8% year-over-year, from $73.64M to $106.59M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s SG&A?: Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s SG&A has grown at a 24.4% compound annual growth rate (CAGR), from $118.96M to $284.8M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Collegium Pharmaceutical, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Collegium Pharmaceutical, Inc. COLL SG&A

SG&A at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Collegium Pharmaceutical, Inc.'s sg&a.